Predict your next investment

HEALTHCARE | Drug Development

See what CB Insights has to offer

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price


About AbCellera

AbCellera (NASDAQ: ABCL) provides technologies to biotechnology and pharmaceutical partners with the goal of discovery and development of monoclonal antibody therapies. Its single-cell platform integrates end-to-end capabilities for therapeutic antibody discovery through a combination of technologies including proprietary immunizations, microfluidics, high-throughput imaging, genomics, computation, and laboratory automation.

AbCellera Headquarter Location

2215 Yukon Street

Vancouver, British Columbia, V5Y 0A1,



Latest AbCellera News

AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer

Dec 2, 2021

December 02, 2021 09:00 AM Eastern Standard Time VANCOUVER, British Columbia--( BUSINESS WIRE )-- AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, announced today the appointment of Neil Aubuchon as Chief Commercial Officer (CCO). Mr. Aubuchon brings over 20 years of experience in strategic planning, operations, and leadership for global biopharmaceutical companies, including tenures at Amgen and Eli Lilly and Company (Lilly). As Chief Commercial Officer, Mr. Aubuchon will lead the commercial strategy and assessment of partnership opportunities to optimize the value of AbCellera’s growing portfolio of royalty positions in the next generation of antibody-based therapies. “AbCellera is selective in partnering and evaluates potential programs from the perspective of targets, teams, technical feasibility, and market opportunity,” said Carl Hansen, Ph.D., CEO and President of AbCellera. “Neil brings significant commercial experience and a unique perspective for evaluating partnership opportunities. We welcome him to our team, and believe his skills will be invaluable as we continue to expand our business and evolve our deal structures.” “AbCellera has established a powerful technology for antibody drug discovery that can quickly translate scientific discovery into new therapies,” said Mr. Aubuchon. “Their technology leadership and market position provide an exciting foundation from which to grow the business. I am excited to join AbCellera, and I look forward to leading efforts that will ultimately result in treatments for patients in need.” Prior to joining AbCellera, Mr. Aubuchon was the Global Marketing Lead for Amgen's General Medicine early portfolio. In this role, he was responsible for developing the integrated strategy for Amgen's non-oncology therapeutic areas and leading commercial strategy for more than 10 biologics, as well as several high profile corporate initiatives. Prior to Amgen, Mr. Aubuchon was the Vice President of Global Marketing at Santen, a global ophthalmology-focused pharmaceutical company. Mr. Aubuchon previously spent nearly 17 years at Lilly in various commercial roles including, Chief Marketing Officer in Australia, Chief Marketing Officer in Japan, Head of Strategy & Operations for Lilly Bio-Medicines Globally, and Vice President of Lilly Bio-Medicines in Japan. About AbCellera Biologics Inc. AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit . AbCellera Forward-looking Statements This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law. Source: AbCellera Biologics Inc.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing AbCellera

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned AbCellera in 5 CB Insights research briefs, most recently on Sep 28, 2020.

Expert Collections containing AbCellera

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AbCellera is included in 3 Expert Collections, including Artificial Intelligence.


Artificial Intelligence

7,904 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.


Digital Health 150

150 items

The winners of the second annual CB Insights Digital Health 150.


Digital Health

11,293 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

AbCellera Patents

AbCellera has filed 1 patent.

The 3 most popular patent topics include:

  • Betacoronaviruses
  • COVID-19
  • Chronic fatigue syndrome
patents chart

Application Date

Grant Date


Related Topics



Betacoronaviruses, Coronaviridae, COVID-19, Viral respiratory tract infections, Chronic fatigue syndrome


Application Date


Grant Date


Related Topics

Betacoronaviruses, Coronaviridae, COVID-19, Viral respiratory tract infections, Chronic fatigue syndrome



AbCellera Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

AbCellera Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.